TNF Family Members in Immunology, Virology and Cancer Therapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 4369
Special Issue Editor
Interests: TNF receptor members; cross-talks between TNF receptors such as Fas and conventional chemotherapeutic drugs; molecular mechanisms underlying TNFR1 pleiotropic signaling; TRAIL signal transduction
Special Issue Information
Dear Colleagues,
TNF family members display pleiotropic functions. While most of them play a critical role in the immune system, like TNF, only a restricted number are naturally involved and necessary to remove unwanted cells infected by viruses or undergoing transformation. Amongst them TNF-Related Apoptosis-Inducing Ligand (TRAIL), whose binding to its cognate agonist receptors, namely TRAIL-R1/DR4 or TRAIL-R2/DR5 triggers cell death in virally-infected or cancer cells. TNF on the other hand is rather associated with pro-inflammatory functions and its ability to trigger cancer cell death is almost inexistent, unless the NF-kB pathway is shut down. Given that TRAIL administration in vivo is safe, contrary to TNF, TRAIL or its derivatives have has attracted major interest in oncology. Notwithstanding, because inhibition of TNF during anti-PD1 or -PDL1 antitumor therapies is emerging as a good opportunity to overcome resistance to cancer-immunotherapies, rational design and targeting of other members of the TNF family may provide as well novel opportunities in anti-cancer therapies or autoimmune diseases. Because recent evidence indicate that TRAIL receptors may in addition trigger non-apoptotic signaling, cell death upon unresolved ER stress regardless of TRAIL, promote stress-induced inflammation or regulate immune cell activity during viral infections, a better understanding of the TRAIL system or the discovery of novel molecules or means to restore TRAIL-induced apoptosis is likely to open novel therapeutic opportunities in oncology, immune and infectious.
This special issue aims at gathering the most recent findings on TNF/TNFR superfamily members in immunology, virology and cancer therapy. Original articles and reviews are welcome.
Dr. Olivier Micheau
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- TNFSF
- TNFRSF
- Cancer
- autoimmune diseases
- infectious diseases
- oncology
- immunology
- virology
- signaling
- therapy
